Abstract
Surgical resection is the standard treatment for patients with early stage nonsmall cell lung cancer, but after surgical resection alone, disease recurrence is frequently seen. Adjuvant chemotherapy has the potential to improve outcomes by eliminating micrometastatic disease before it can become clinically evident. A number of large clinical trials have been performed to determine the utility of this approach. Early trials did not show a benefit, but more recent randomized studies using cisplatin-based chemotherapy regimens have shown an absolute survival benefit of about 5% at five years. In this chapter, we will review clinical trial data, discuss which patients are good candidates for adjuvant chemotherapy, and address several questions which are currently under active investigation.
Original language | English (US) |
---|---|
Title of host publication | Lung Cancer |
Subtitle of host publication | Fourth Edition |
Publisher | Wiley-Blackwell |
Pages | 278-289 |
Number of pages | 12 |
ISBN (Electronic) | 9781118468791 |
ISBN (Print) | 9781118468746 |
DOIs | |
State | Published - May 27 2014 |
Keywords
- Adjuvant treatment
- Biomarkers
- Chemotherapy
- Lung cancer
- Targeted therapy
ASJC Scopus subject areas
- General Medicine